Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial-Reference-Cited by-同舟云学术

Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial

Published:2021-01 Issue:1 Volume:32 Page:66-76
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Petrelli F.,Rulli E.,Labianca R.,Lonardi S.,Rosati G.,Dotti K.,Ronzoni M.,Pella N.,Pusceddu V.,Banzi M.,Zampino M.G.,Yasmina M.,Marchetti P.,Cantore M.,Zaniboni A.,Rimassa L.,Ciuffreda L.,Ferrari D.,Zagonel V.,Maiello E.,Sobrero A.

Funder

Agenzia Italiana del Farmaco

Gruppo Italiano Studio Carcinomi Apparato Digerente

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference11 articles.

1. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study;André;J Clin Oncol,2015

2. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;André;J Clin Oncol,2009

3. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101;Shulman;J Clin Oncol,2012

4. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis;Inno;Breast Cancer Res Treat,2019

5. FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial;Sobrero;J Clin Oncol,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR);Digestive and Liver Disease;2024-05

2. Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment;Annals of Coloproctology;2024-04-30

3. Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis;International Journal of Surgery;2024-02-13

4. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial;ESMO Open;2023-12

5. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice;Cancer Treatment Reviews;2023-12